Top State
...

Sanders-Brown director’s drug candidate advances to Alzheimer’s clinical trial

For nearly two decades Linda Van Eldik, Ph.D., director of University of Kentucky’s Sanders-Brown Center on Aging, has worked toward a goal: developing a drug that could help protect the brain from the damaging inflammation associated with Alzheimer’s disease. 

Now, a new grant from the National Institute on Aging will help her and a team of collaborators take the next step — testing the drug candidate in people with mild cognitive impairment or early Alzheimer’s disease. 

The approximately $4 million award supports the initial phase of the STORM study, which stands for STudies of ORal MW189. The project will evaluate an experimental oral drug called MW189 that is designed to reduce harmful inflammation in the brain. This is a different approach to a disease that affects memory, thinking and everyday life. 

“I have been working toward this milestone for almost two decades,” said Van Eldik. “It is beyond exciting that we are finally going to be able to do this clinical study and test this promising drug candidate that targets an important mechanism driving Alzheimer’s disease progression.” 

Targeting inflammation in the brain 

Inflammation is part of the body’s normal response to injury or disease. But when that response becomes excessive or continues too long, it can contribute to damage. 

In Alzheimer’s disease, brain cells involved in the immune response can produce too many inflammatory proteins called cytokines. That imbalance can interfere with communication between nerve cells and contribute to problems with memory and thinking. 

MW189 is designed to reduce that excessive inflammatory response. In animal studies, the drug helped protect the connections between nerve cells and reduced cognitive impairment. 

While recently approved Alzheimer’s treatments target amyloid — a protein that forms plaques in the brain — MW189 targets inflammation. Researchers hope that approach could eventually offer another treatment option, either on its own or alongside other therapies. 

“MW189 can also be used in patients who are on antiamyloid therapy, providing an additional and potentially complementary mechanism to be targeted in this patient population,” Van Eldik said. 

Whether the drug benefits people with Alzheimer’s remains a question for clinical research. 

Taking the next step 

MW189 has previously been studied through short-term intravenous administration in healthy adults and is being evaluated in a clinical trial involving patients with hemorrhagic stroke, or bleeding in the brain. 

STORM will be the first study to test repeated daily oral doses of MW189 in people with mild cognitive impairment or early Alzheimer’s disease. 

The initial phase 2a study is expected to enroll 24 participants across four clinical sites, including UK. Researchers will evaluate three dose levels to learn more about the drug’s safety, how well participants tolerate it and the drug levels reached in the blood. 

Participants will receive both the study drug and a placebo at different points in the trial. This design means every participant will receive MW189 during at least one treatment period. 

The findings will help researchers select a dose for a potential second phase involving 12 months of daily oral treatment. Funding for that phase will depend on the team’s progress and completion of required milestones. 

The study is too small to establish whether MW189 effectively treats Alzheimer’s disease. However, researchers will look for signals that could support larger trials, including changes in inflammatory proteins, markers of Alzheimer’s disease, brain imaging and cognitive testing. 

A collaborative effort 

Van Eldik leads the project with Daniel Hanley, M.D., of Johns Hopkins University, and D. Martin Watterson, Ph.D., of Northwestern University. Johns Hopkins serves as the lead institution for the grant. 

At UK, the team includes Gregory Jicha, M.D., Ph.D., who will lead the UK clinical site, and Erin Abner, Ph.D., whose expertise includes clinical study design and data analysis. 

Researchers hope to begin recruitment in early 2027, following completion of drug preparation, regulatory requirements and clinical site preparations. UK participants will be enrolled through the Sanders-Brown Turfland Clinic. 

For Van Eldik, the project reflects the value of bringing laboratory researchers, clinical investigators and data experts together to move discoveries toward patient care. 

“Sanders-Brown Center on Aging has a major focus on supporting research that aims to move our basic science discoveries as rapidly as possible to human applications,” she said. “We have developed the infrastructure and expertise to support — basic, translational and clinical work — which enables researchers to develop teams and collaborations with the right skills to succeed.” 

Nearly two decades in the making 

The first publication describing the class of compounds that includes MW189 appeared in 2007. Even then, Van Eldik hoped the work would eventually lead to an Alzheimer’s clinical trial. 

Getting there required years of research to understand the drug’s effects, evaluate its safety and prepare it for testing in people. 

“Because of the time and expense required, it is highly unusual for an academic researcher to be able to create a drug candidate and move it all the way through the drug discovery/development continuum into successful human clinical trials,” Van Eldik said. 

STORM represents an opportunity to learn whether that work could lead to a new way of addressing Alzheimer’s disease. If the findings support further development, larger studies would be needed to determine whether MW189 can slow disease progression. 

“I always wanted to develop it for an Alzheimer’s clinical trial,” Van Eldik said. 

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers R01AG069930, U01AG028561, U01AG050636, U01AG076480, UG3AG10411. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.  

Research reported in this publication was also supported by the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. 

UK HealthCare is the hospitals and clinics of the University of Kentucky. But it is so much more. It is more than 10,000 dedicated healthcare professionals committed to providing advanced subspecialty care for the most critically injured and ill patients from the Commonwealth and beyond. It also is the home of the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, a Level IV Neonatal Intensive Care Unit that cares for the tiniest and sickest newborns and the region’s only Level 1 trauma center.

As an academic research institution, we are continuously pursuing the next generation of cures, treatments, protocols and policies. Our discoveries have the potential to change what’s medically possible within our lifetimes. Our educators and thought leaders are transforming the healthcare landscape as our six health professions colleges teach the next generation of doctors, nurses, pharmacists and other healthcare professionals, spreading the highest standards of care. UK HealthCare is the power of advanced medicine committed to creating a healthier Kentucky, now and for generations to come. 

Linda Van Eldik, Ph.D., in her lab at UK’s Sanders-Brown Center on Aging. Mark Cornelison | UK Creative Services

8 hours ago